Bristol Myers Squibb (CELG-RI) Non-Current Deffered Revenue (2009 - 2019)

Bristol Myers Squibb (CELG-RI) has 11 years of Non-Current Deffered Revenue data on file, last reported at $448.0 million in Q1 2019.

• Non-Current Deffered Revenue for Q1 2019 came in at $448.0 million, changed 0.22% year-over-year; the trailing twelve-month figure through Mar 2019 was $448.0 million (changed 0.22% YoY), and the FY2018 annual result was $468.0 million, up 3.08% from the prior year.
• Non-Current Deffered Revenue retreated to $448.0 million in Q1 2019 per CELG-RI's latest filing, from $468.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $697.0 million in Q1 2015 and troughed at $447.0 million in Q1 2018.
• A 5-year average of $542.5 million and a median of $528.0 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2015 and 2018: Non-Current Deffered Revenue sank 35.99% in 2015, then rose 3.08% in 2018.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $586.0 million in 2015, then declined by 6.66% to $547.0 million in 2016, then dropped by 17.0% to $454.0 million in 2017, then rose by 3.08% to $468.0 million in 2018, then dropped by 4.27% to $448.0 million in 2019.
• Business Quant data shows CELG-RI's Non-Current Deffered Revenue at $448.0 million in Q1 2019, $468.0 million in Q4 2018, and $486.0 million in Q3 2018.